A Phase 2 interventional study of CIN-107 2 mg dosing and CIN-107 4 mg dosing in Primary Aldosteronism and Hyperaldosteronism, sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Hyperaldosteronism with a site in United States — 4 open to participants now, 7 under way, 1 of them phase 3. Hyperaldosteronism · United States.
Among the 19 studies in Hyperaldosteronism with a site in United States, this one is the only one that started in 2021, is one of 4 in phase 2, and was the 12th registered.
201 studies on the registry are indexed under Hyperaldosteronism; 91 are open to participants now.
Browse Hyperaldosteronism studies →4 of the 19 studies in Hyperaldosteronism with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Brigham and Women's Hospital · Sites in United States
Ages 18–85
Duke University · Sites in United States, Canada
Ages 0–20 · Healthy volunteers
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 7–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Hyperaldosteronism studies recruiting now, 22 (32%) set no upper age limit and 30 (44%) stop at 75 or younger; 6 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 1981; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 63 across 94 interventional studies indexed under Hyperaldosteronism.
Median enrollment 41 across the 9 interventional studies, 514 across the 9 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Hyperaldosteronism — fewer than ten, so there is no comparison to draw.
4 of the studies in Hyperaldosteronism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07007793Phase 3AstraZenecaParent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study. | 2027-07-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT03374215National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks | 2026-12-31 |
| NCT05030545Brigham and Women's HospitalCardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Hyperaldosteronism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part 2 for up to 74 weeks for evidence of long-term safety and tolerability.
For patients in Part 1 only :
The treatment duration for patients who complete all 3 dose levels, and who opt not to continue in the extension part of the study, is 12 weeks. For patients who do not complete up-titration, the treatment duration will include at least 4 weeks of dosing with the final dose level. If down-titration of CIN-107 dose is determined at Visit 6 (Week 9), the total treatment duration may be extended to 13 weeks to allow sufficient time for CIN-107 treatment effect at the final dose to be assessed. If the final dose of CIN-107 is reached before week 8 (Visit 5) and no up-titration occurs at Visit 5, the patients will be encouraged to continue CIN-107 treatment till Visit 7 for a total of 12 weeks of treatment. The patients who opt not to continue to Part 2 will not receive any study drug and will return for their safety follow up visit (Visit 8) in 2 weeks.
For patients who opt to continue in the extension part (Part 2) of the study:
Patients will continue to receive their dose of baxdrostat and be instructed to measure BP at least once every week prior to dosing with CIN-107 in the morning, during the extension phase. Safety surveillance will be conducted if clinically indicated. Repeat and unscheduled testing for serum potassium may be measured at the investigator's clinical site or at local laboratory for a faster turn-around time to allow clinical assessment. These patients entering part 2 will skip Visit 8 and their next visit will be Visit 9.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be provided with an initial dose of CIN-107 and start once daily (QD) dosing of CIN-107 tablets at 2 mg. At Visit 4, CIN-107 dose may be up-titrated to 4 mg QD if the patient has tolerated dosing of CIN-107 at 2 mg and the blood pressure (BP) records indicate minimal hypotension risk. At Visit 5, CIN-107 dose may be up-titrated to 8 mg QD if the patient has tolerated dosing of CIN-107 at 4 mg.
Drug: CIN-107 2 mg dosing · Drug: CIN-107 4 mg dosing · Drug: CIN-107 8 mg dosing
One tablet of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 2 mg.
Two tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 4 mg.
Four tablets of CIN-107 2 mg tablets, once daily, by mouth, for dosing at 8 mg.
Number of Treatment Emergent Adverse Events
An AE is defined as any untoward medical occurrence in a clinical investigation that occurs to a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Adverse events were collected from the beginning of the study until Week 74. Treatment emergent AEs are defined as AEs that newly occur or worsen in severity during the treatment period.
Time frame: 74 weeks
Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism
The mean seated SBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean seated SBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
Time frame: 12 weeks
Change From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism
The mean DBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean DBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
Time frame: 12 weeks
The Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg
The percentage of patients achieving a mean seated SBP \<140 mmHg and a mean DBP of \<90 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
Time frame: 12 weeks
The Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg
The percentage of patients achieving a mean seated SBP \<130 mmHg and a mean DBP of \<80 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
Time frame: 12 weeks
The Percentage of Patients Achieving the Pharmacodynamic Marker Response
Pharmacodynamic marker response is defined as achieving either: - a plasma aldosterone concentration (PAC) \< 15 ng/dL and a plasma renin activity (PRA) ≥ 0.5 ng/mL/h; or - an ARR \< 15; or - unsuppressed renin activity PRA ≥ 1.0 ng/mL/h
Time frame: 12 weeks
The study was conducted from 08 March 2021 to 28 October 2024 at 10 sites in United States
| Milestone | CIN-107 |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
| Milestone | CIN-107 |
|---|---|
| Started | 14 |
| Completed | 12 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 1 |
An AE is defined as any untoward medical occurrence in a clinical investigation that occurs to a patient administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Adverse events were collected from the beginning of the study until Week 74. Treatment emergent AEs are defined as AEs that newly occur or worsen in severity during the treatment period.
| Number of events | CIN-107 |
|---|---|
| Part 1 before titration (0-Week 4) | 27 |
| Part 1 after titration (Week 4-Week 12) | 34 |
| Part 2 (Week 12-Week 74) | 101 |
The mean seated SBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean seated SBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
| mmHg | CIN-107 |
|---|---|
| Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) in Patients With Primary Aldosteronism | -24.9 ± 11.6 |
The mean DBP was defined as the average of 3 measurements obtained at the clinical site visit. The change from baseline in mean DBP after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
| mmHg | CIN-107 |
|---|---|
| Change From Baseline in Mean Diastolic Blood Pressure (DBP) in Patients With Primary Aldosteronism | -10.6 ± 8.95 |
The percentage of patients achieving a mean seated SBP \<140 mmHg and a mean DBP of \<90 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
| Participants | CIN-107 |
|---|---|
| The Percentage of Patients Achieving a Seated BP Response of <140/90 mmHg | 11 |
The percentage of patients achieving a mean seated SBP \<130 mmHg and a mean DBP of \<80 mmHg after 12 weeks of treatment with CIN-107 (Part 1) is calculated.
| Participants | CIN-107 |
|---|---|
| The Percentage of Patients Achieving a Seated BP Response of <130/80 mmHg | 6 |
Pharmacodynamic marker response is defined as achieving either: - a plasma aldosterone concentration (PAC) \< 15 ng/dL and a plasma renin activity (PRA) ≥ 0.5 ng/mL/h; or - an ARR \< 15; or - unsuppressed renin activity PRA ≥ 1.0 ng/mL/h
| Participants | CIN-107 |
|---|---|
| The Percentage of Patients Achieving the Pharmacodynamic Marker Response | 12 |
Collected over From first dose of study drug to the end of the study at week 74. Note that the study was divided in 2 parts: Part 1 starting at the date of first dose and ending at Week 12 with an additional safety follow-up at Week 14 for those opting out of part 2 while Part 2 starts at Week 12 and ends at Week 72 with an additional safety follow-up at Week 74.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CIN-107 2 mg Part 1 - Before Titration | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| CIN-107 2 mg Part 1 - After Titration | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| CIN-107 4 mg Part 1 - After Titration | 0/13 (0%) | 0/13 (0%) | 8/13 (61.5%) |
| CIN-107 8 mg Part 1 - After Titration | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| CIN-107 2 mg Part 2 | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| CIN-107 4 mg Part 2 | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| CIN-107 8 mg Part 2 | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | CIN-107 2 mg Part 1 - Before Titration | CIN-107 2 mg Part 1 - After Titration | CIN-107 4 mg Part 1 - After Titration | CIN-107 8 mg Part 1 - After Titration | CIN-107 2 mg Part 2 | CIN-107 4 mg Part 2 | CIN-107 8 mg Part 2 |
|---|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 0/15 | 0/3 | 0/13 | 0/8 | 0/4 | 0/7 | 1/7 |
| Event | CIN-107 2 mg Part 1 - Before Titration | CIN-107 2 mg Part 1 - After Titration | CIN-107 4 mg Part 1 - After Titration | CIN-107 8 mg Part 1 - After Titration | CIN-107 2 mg Part 2 | CIN-107 4 mg Part 2 | CIN-107 8 mg Part 2 |
|---|---|---|---|---|---|---|---|
| PalpitationsCardiac disorders | 0/15 | 0/3 | 1/13 | 0/8 | 2/4 | 0/7 | 0/7 |
| Blood creatinine increasedInvestigations | 0/15 | 0/3 | 0/13 | 0/8 | 2/4 | 0/7 | 1/7 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/15 | 0/3 | 1/13 | 0/8 | 2/4 | 3/7 | 1/7 |
| Asymptomatic bacteriuriaInfections and infestations | 0/15 | 1/3 | 0/13 | 0/8 | 0/4 | 0/7 | 0/7 |
| ProteinuriaRenal and urinary disorders | 0/15 | 1/3 | 0/13 | 0/8 | 0/4 | 0/7 | 0/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/15 | 1/3 | 0/13 | 0/8 | 1/4 | 1/7 | 0/7 |
| Oedema peripheralGeneral disorders | 0/15 | 0/3 | 0/13 | 0/8 | 0/4 | 0/7 | 2/7 |
| Covid-19Infections and infestations | 0/15 | 0/3 | 1/13 | 0/8 | 1/4 | 0/7 | 2/7 |
| HeadacheNervous system disorders | 4/15 | 0/3 | 2/13 | 0/8 | 0/4 | 2/7 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 0/15 | 0/3 | 0/13 | 0/8 | 1/4 | 0/7 | 2/7 |
ITT Population defined as all participants enrolled in the study. Due to the small sample size of the study, arms/groups are combined for analysis.
| Age, Continuous(Years) | CIN-107 |
|---|---|
| Mean | 53.6 ± 11.6 |
| Sex: Female, Male(Participants) | CIN-107 |
|---|---|
| Female | 5 |
| Male | 10 |
| Race/Ethnicity, Customized(Participants) | CIN-107 |
|---|---|
| WHITE | 7 |
| BLACK OR AFRICAN AMERICAN | 4 |
| ASIAN | 3 |
| Other | 1 |
| Region of Enrollment(Participants) | CIN-107 |
|---|---|
| USA | 15 |
| Seated SBP(mmHg) | CIN-107 |
|---|---|
| Mean | 151.5 ± 13.46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Mar 2021 to primary completion in Oct 2024, 43 months.
Results were first posted in Mar 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baxdrostat